Bank of America Corp DE Sells 14,504 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Bank of America Corp DE decreased its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 29.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,187 shares of the company's stock after selling 14,504 shares during the period. Bank of America Corp DE owned approximately 0.07% of Enliven Therapeutics worth $769,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ELVN. BNP Paribas Financial Markets bought a new stake in shares of Enliven Therapeutics in the 4th quarter worth approximately $112,000. Ameriprise Financial Inc. bought a new position in Enliven Therapeutics in the fourth quarter worth $789,000. Boxer Capital Management LLC acquired a new stake in Enliven Therapeutics during the fourth quarter worth $15,106,000. Northern Trust Corp boosted its stake in Enliven Therapeutics by 8.9% during the fourth quarter. Northern Trust Corp now owns 331,500 shares of the company's stock worth $7,459,000 after buying an additional 27,104 shares in the last quarter. Finally, Artia Global Partners LP bought a new stake in Enliven Therapeutics in the 4th quarter valued at $2,315,000. Institutional investors own 95.08% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ELVN. Jones Trading reduced their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. HC Wainwright raised their price target on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $37.25.

Insider Activity

In other news, CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $21.33, for a total value of $69,322.50. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares in the company, valued at approximately $490,590. This trade represents a 12.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $20.83, for a total transaction of $260,375.00. Following the completion of the transaction, the chief executive officer now directly owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. This represents a 1.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 94,444 shares of company stock worth $1,801,057. Insiders own 25.90% of the company's stock.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $20.74 on Monday. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03. The business has a fifty day moving average of $18.08 and a two-hundred day moving average of $20.78. The stock has a market cap of $1.02 billion, a PE ratio of -10.92 and a beta of 0.79.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Want to see what other hedge funds are holding ELVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.